Ignite Creation Date:
2024-05-05 @ 4:56 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00351871
Status:
COMPLETED
Last Update Posted:
2009-02-04
First Post:
2006-07-12
Brief Title:
Influence of Marker of Insulin Resistance Upon Hepatitis C Virus HCV Treatment Responses to PEG Intron and Rebetol Therapy
Sponsor:
Louisiana State University Health Sciences Center in New Orleans
Organization:
Louisiana State University Health Sciences Center in New Orleans
Study Overview
Official Title:
Influence of Marker of Insulin Resistance Upon HCV Treatment Responses to PEG Intron and Rebetol Therapy
Status:
COMPLETED
Status Verified Date:
2009-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this study is to better understand the influence of insulin resistance upon treatment response in hepatitis C virus treated with PEG Intron and Rebetol
Detailed Description:
The relationship between HCV and IR is an evolving one This study will allow a more formal evaluation of this relationship Four hundred patients will be treated using weight based Peg Intron and Rebetol Clinical and biochemical data related to IR will be collected to determine if any such factors can predict who will have a sustained virological response To evaluate patients for insulin resistance the HOMA score the product of the fasting insulin level and blood glucose level waist circumference and body mass index will be measured
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None